Airline Missed Chance to Prevent Plane Crash: Safety Report

Avalo Therapeutics (AVTX) has appointed Rita Jain, M.D. as a new board member, bringing valuable insights to the company's strategic direction and growth. Analysts forecast an average target price of $29.88, implying a 568.34% upside from the current price of $4.47. The average brokerage recommendation is "Buy," and the estimated GF Value in one year is $0.07, suggesting a downside of 98.43% from the current price.

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, has appointed Dr. Rita Jain, M.D., to its Board of Directors. The appointment was announced on June 18, 2025, and marks a significant addition to the company's leadership team as it advances its lead asset, AVTX-009, an anti-IL-1β monoclonal antibody currently in a Phase 2 trial for hidradenitis suppurativa (HS).

Dr. Jain brings over two decades of leadership experience in biopharmaceutical development, clinical strategy, and regulatory affairs across multiple therapeutic areas, including immunology, inflammation, nephrology, and rare diseases. She most recently served as Executive Vice President and Chief Medical Officer at ChemoCentryx, where she advanced development and supported commercialization of Tavneos® (avacopan), a first-in-class treatment for ANCA-associated vasculitis, and supported the company’s acquisition by Amgen in 2022. Prior to that, she held key leadership positions at Akebia Therapeutics, AbbVie, Pfizer, and Immunovant, overseeing global development programs, regulatory interactions, and clinical operations for multiple therapeutic candidates. She also serves on the boards of Celldex Therapeutics and AnaptysBio.

“We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thoughtful, capital-efficient approach to our broader development strategy.”

“I am excited to join Avalo’s Board at this pivotal stage in the company’s growth, with the progressing Phase 2 LOTUS trial in HS expected to readout in the middle of next year,” said Dr. Jain. “I was drawn to this opportunity given AVTX-009's proven mechanism of action, its potential to become a best-in-disease treatment in HS, and its potential in addressing unmet needs in a number of additional large inflammatory diseases. With my experience in navigating strategic growth in immunology and inflammation across multiple indications and stages of development, I look forward to supporting the leadership team and collaborating with my fellow Board members as Avalo works to bring potential best-in-disease treatments to patients in need.”

Analysts have forecast an average target price of $29.88 for Avalo Therapeutics, implying a 568.34% upside from the current price of $4.47. The average brokerage recommendation is "Buy," and the estimated GF Value in one year is $0.07, suggesting a downside of 98.43% from the current price.

The appointment of Dr. Jain underscores Avalo Therapeutics' commitment to advancing its pipeline and addressing unmet medical needs in inflammatory diseases. With her extensive experience and strategic insights, Dr. Jain is well-positioned to contribute to Avalo's growth and success.

References:
[1] https://www.biospace.com/press-releases/avalo-therapeutics-announces-appointment-of-rita-jain-m-d-to-board-of-directors
[2] https://www.nasdaq.com/articles/avalo-therapeutics-appoints-dr-rita-jain-board-directors